141 related articles for article (PubMed ID: 29948022)
1. Over-adherence to capecitabine: a potential safety issue in breast and colorectal cancer patients.
Le Saux O; Bourmaud A; Rioufol C; Colomban O; Guitton J; Schwiertz V; Regnier V; You B; Ranchon F; Maraval-Gaget R; Girard P; Chauvin F; Freyer G; Tod M; Henin E; Trillet-Lenoir V
Cancer Chemother Pharmacol; 2018 Aug; 82(2):319-327. PubMed ID: 29948022
[TBL] [Abstract][Full Text] [Related]
2. Adherence to oral anticancer chemotherapy: What influences patients' over or non-adherence? Analysis of the OCTO study through quantitative-qualitative methods.
Bourmaud A; Henin E; Tinquaut F; Regnier V; Hamant C; Colomban O; You B; Ranchon F; Guitton J; Girard P; Freyer G; Tod M; Rioufol C; Trillet-Lenoir V; Chauvin F
BMC Res Notes; 2015 Jul; 8():291. PubMed ID: 26142140
[TBL] [Abstract][Full Text] [Related]
3. [Validation of a questionnaire assessing patients' adherence and skill level of management for oral capecitabine treatment].
Baudot A; Oriol M; Tinquaut F; Moine V; Moriceau G; Muron T; Pacaut C; Collard O; Jacquin JP; Saban-Roche L; Bosacki C; Regnier-Denois V; Chauvin F; Bourmaud A
Bull Cancer; 2016 Mar; 103(3):241-51. PubMed ID: 26917467
[TBL] [Abstract][Full Text] [Related]
4. Adherence and persistence with oral adjuvant chemotherapy in older women with early-stage breast cancer in CALGB 49907: adherence companion study 60104.
Partridge AH; Archer L; Kornblith AB; Gralow J; Grenier D; Perez E; Wolff AC; Wang X; Kastrissios H; Berry D; Hudis C; Winer E; Muss H
J Clin Oncol; 2010 May; 28(14):2418-22. PubMed ID: 20368559
[TBL] [Abstract][Full Text] [Related]
5. Clinical evaluation of germline polymorphisms associated with capecitabine toxicity in breast cancer: TBCRC-015.
O'Donnell PH; Trubetskoy V; Nurhussein-Patterson A; Hall JP; Nath A; Huo D; Fleming GF; Ingle JN; Abramson VG; Morrow PK; Storniolo AM; Forero A; Van Poznak C; Liu MC; Chang JC; Merkel DE; Peppercorn JM; Rugo HS; Dees EC; Hahn OM; Hoffman PC; Rosner GL; Huang RS; Ratain MJ; Cox N; Olopade OI; Wolff AC; Dolan ME; Nanda R;
Breast Cancer Res Treat; 2020 Jun; 181(3):623-633. PubMed ID: 32378051
[TBL] [Abstract][Full Text] [Related]
6. Study on adherence to capecitabine among patients with colorectal cancer and metastatic breast cancer.
Figueiredo Junior AG; Forones NM
Arq Gastroenterol; 2014; 51(3):186-91. PubMed ID: 25296077
[TBL] [Abstract][Full Text] [Related]
7. Enhancing adherence to capecitabine chemotherapy by means of multidisciplinary pharmaceutical care.
Simons S; Ringsdorf S; Braun M; Mey UJ; Schwindt PF; Ko YD; Schmidt-Wolf I; Kuhn W; Jaehde U
Support Care Cancer; 2011 Jul; 19(7):1009-18. PubMed ID: 20552377
[TBL] [Abstract][Full Text] [Related]
8. Clinical features of oral chemotherapy: results of a longitudinal prospective study of breast and colorectal cancer patients receiving capecitabine in the UK.
Brearley SG; Craven O; Saunders M; Swindell R; Molassiotis A
Eur J Cancer Care (Engl); 2010 Jul; 19(4):425-33. PubMed ID: 19708942
[TBL] [Abstract][Full Text] [Related]
9. Capecitabine non-adherence: exploration of magnitude, nature and contributing factors.
Bhattacharya D; Easthall C; Willoughby KA; Small M; Watson S
J Oncol Pharm Pract; 2012 Sep; 18(3):333-42. PubMed ID: 22298660
[TBL] [Abstract][Full Text] [Related]
10. Assessing adherence to oral chemotherapy using different measurement methods: Lessons learned from capecitabine.
Walter T; Wang L; Chuk K; Ng P; Tannock IF; Krzyzanowska MK
J Oncol Pharm Pract; 2014 Aug; 20(4):249-56. PubMed ID: 24022406
[TBL] [Abstract][Full Text] [Related]
11. Accelerated versus standard epirubicin followed by cyclophosphamide, methotrexate, and fluorouracil or capecitabine as adjuvant therapy for breast cancer in the randomised UK TACT2 trial (CRUK/05/19): a multicentre, phase 3, open-label, randomised, controlled trial.
Cameron D; Morden JP; Canney P; Velikova G; Coleman R; Bartlett J; Agrawal R; Banerji J; Bertelli G; Bloomfield D; Brunt AM; Earl H; Ellis P; Gaunt C; Gillman A; Hearfield N; Laing R; Murray N; Couper N; Stein RC; Verrill M; Wardley A; Barrett-Lee P; Bliss JM;
Lancet Oncol; 2017 Jul; 18(7):929-945. PubMed ID: 28600210
[TBL] [Abstract][Full Text] [Related]
12. Trastuzumab emtansine versus capecitabine plus lapatinib in patients with previously treated HER2-positive advanced breast cancer (EMILIA): a descriptive analysis of final overall survival results from a randomised, open-label, phase 3 trial.
DiƩras V; Miles D; Verma S; Pegram M; Welslau M; Baselga J; Krop IE; Blackwell K; Hoersch S; Xu J; Green M; Gianni L
Lancet Oncol; 2017 Jun; 18(6):732-742. PubMed ID: 28526536
[TBL] [Abstract][Full Text] [Related]
13. Population pharmacokinetics and concentration-effect relationships of capecitabine metabolites in colorectal cancer patients.
Gieschke R; Burger HU; Reigner B; Blesch KS; Steimer JL
Br J Clin Pharmacol; 2003 Mar; 55(3):252-63. PubMed ID: 12630975
[TBL] [Abstract][Full Text] [Related]
14. A comparison of toxicity profiles between the lower and standard dose capecitabine in breast cancer: a systematic review and meta-analysis.
Nishijima TF; Suzuki M; Muss HB
Breast Cancer Res Treat; 2016 Apr; 156(2):227-36. PubMed ID: 26988358
[TBL] [Abstract][Full Text] [Related]
15. Possible Pathways of Capecitabine-Induced Hand-Foot Syndrome.
Lou Y; Wang Q; Zheng J; Hu H; Liu L; Hong D; Zeng S
Chem Res Toxicol; 2016 Oct; 29(10):1591-1601. PubMed ID: 27631426
[TBL] [Abstract][Full Text] [Related]
16. Continuous, low-dose capecitabine for patients with recurrent colorectal cancer.
Romiti A; Onesti CE; Roberto M; Barucca V; Tomao S; D'Antonio C; Durante V; Milano A; Falcone R; Di Rocco R; Righini R; Marchetti P
Med Oncol; 2015 Mar; 32(3):54. PubMed ID: 25638466
[TBL] [Abstract][Full Text] [Related]
17. Safety profile and activity of lower capecitabine dose in patients with metastatic breast cancer.
Rossi D; Alessandroni P; Catalano V; Giordani P; Fedeli SL; Fedeli A; Baldelli AM; Casadei V; Ceccolini M; Catalano G
Clin Breast Cancer; 2007 Dec; 7(11):857-60. PubMed ID: 18269775
[TBL] [Abstract][Full Text] [Related]
18. Adverse reactions and adherence to capecitabine: A prospective study in patients with gastrointestinal cancer.
Visacri MB; Duarte NC; Lima TM; de Souza RN; Cobaxo TS; Teixeira JC; Barbosa CR; Dias LP; Tavares MG; Pincinato EC; Lima CS; Moriel P
J Oncol Pharm Pract; 2022 Mar; 28(2):326-336. PubMed ID: 33470162
[TBL] [Abstract][Full Text] [Related]
19. The Effect of Telephone-Based Follow-Up on Adherence, Efficacy, and Toxicity of Oral Capecitabine-Based Chemotherapy.
Eldeib HK; Abbassi MM; Hussein MM; Salem SE; Sabry NA
Telemed J E Health; 2019 Jun; 25(6):462-470. PubMed ID: 30048216
[No Abstract] [Full Text] [Related]
20. Mapisal Versus Urea Cream as Prophylaxis for Capecitabine-Associated Hand-Foot Syndrome: A Randomized Phase III Trial of the AIO Quality of Life Working Group.
Hofheinz RD; Gencer D; Schulz H; Stahl M; Hegewisch-Becker S; Loeffler LM; Kronawitter U; Bolz G; Potenberg J; Tauchert F; Al-Batran SE; Schneeweiss A
J Clin Oncol; 2015 Aug; 33(22):2444-9. PubMed ID: 26124485
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]